Canaccord Genuity Downgrades Entellus Medical (ENTL) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts ENTL Hot Sheet
Price: $7.74 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Canaccord Genuity downgraded Entellus Medical (NASDAQ: ENTL) from Buy to Hold with a price target of $18.00 (from $22.00).
For an analyst ratings summary and ratings history on Entellus Medical click here. For more ratings news on Entellus Medical click here.
Shares of Entellus Medical closed at $15.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades Bank Rakyat Indonesia Persero Tbk PT (BBRI:IJ) (BKRKF) to Neutral
- BofA Securities Downgrades Central Bancompany (CBC) to Neutral
- BTIG Downgrades Driven Brands (DRVN) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
